21 May 2009
Hyperuricaemia is a mediator of endothelial dysfunction and inflammation in renal allograft recipients
A Karbowska, M Boratyńska, M KlingerAnn Transplant 2009; 14(1): 33-33 :: ID: 880319
Abstract
Hyperuricaemia is common in renal transplant recipients treated with calcineurine inhibitors. Experimental studies suggest that uric acid induces glomerular hypertension, microvascular disease and renal interstitial fibrosis Hyperuricaemia is also an independent risk factor of cardiovascular complications. The mechanism by which uric acid injures renal allograft and cardiovascular system is still unclear. The aim of this study was to assess the influence of serum uric acid level on biomarkers of endothelial dysfunction and inflammation in renal allograft recipients. The study involved 78 adult renal transplant recipients (aged 19-70 years) with stable graft function (creatinine 0.7-1.4 mg/dl). The patients were transplanted between 2003 and 2006. Exclusion criteria were: abnormal renal function, proteinuria, diabetes mellitus, BMI above 30 and inflammation. The immunosuppressive protocol consisted of CsA or tacrolimus and azathioprine or mycophenolate mofetil and prednisone. The patients were divided into 2 groups: I - 48 patients with hyperuricaemia (uric acid 7.72±1.33 mg/dl) and II - 30 patients with normal uric acid level 5.48±0.92 mg/dl (control group). Markers of endothelial function and inflammation were assessed in both groups: plasma resistin level, CD146 and sVCAM-1. No significant differences were found in demographic data between both groups of patients with and without hyperuricaemia, such as age, gender, cause of renal failure, the number of HLA mismatches, DGF and number of episodes of acute rejection. The examined biomarkers were elevated in patients with hyperuricaemia. Resistin level was higher in hyperuricemic patients than in the control group (7.15±2.42 ng/ml vs. 6.29±2.76 ng/ml), and was higher in women (7.83 ng/ml) than in men (6.58 ng/ml). Also sVCAM-1 was significantly higher in hyperuricemic patients (1126±371ng/ml) when compared to patients with normal uric acid level (955±269 ng/ml) P<0.03. Resistin level correlated significantly with sVCAM-1 (P<0.01). CD146 was elevated in patients with hyperuricaemia (389.7±150 ug/ml). Hyperuricaemia mediates endothelial dysfunction and inflammation and may contribute to chronic allograft injury and cardiovascular events in renal allograft recipients.
Keywords: Kidney Transplantation
In Press
06 May 2022 : Original article
Phosphatidylethanol (PEth) for Monitoring Sobriety in Liver Transplant Candidates: Preliminary Results of D...Ann Transplant In Press; DOI: 10.12659/AOT.936293
Most Viewed Current Articles
26 Jan 2022 : Review article
Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive ModelsDOI :10.12659/AOT.934924
Ann Transplant 2022; 27:e934924
29 Dec 2021 : Original article
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588
24 Jul 2020 : Review article
Kidney Transplantation in the Times of COVID-19 – A Literature ReviewDOI :10.12659/AOT.925755
Ann Transplant 2020; 25:e925755
15 Mar 2022 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860